ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GSK Gsk Plc

1,708.60
3.40 (0.20%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 0.20% 1,708.60 1,708.60 1,708.80 1,713.00 1,699.40 1,701.60 11,522,668 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.27 70.34B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,705.20p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,719.80p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £70.34 billion. Gsk has a price to earnings ratio (PE ratio) of 14.27.

Gsk Share Discussion Threads

Showing 10451 to 10470 of 33075 messages
Chat Pages: Latest  423  422  421  420  419  418  417  416  415  414  413  412  Older
DateSubjectAuthorDiscuss
13/3/2015
18:21
Seems so TM :-)

Good bounce today.

philanderer
13/3/2015
12:26
All publicity is good publicity
tradermichael
13/3/2015
10:49
Very touchy those American companies.
2hoggy
12/3/2015
20:48
more or less the same in the Telegraph...


"n the FTSE 100, which enjoyed a second day of gains after adding 0.59pc to 6761.07, topping the leaderboard was drug group Astrazeneca. Hopes of positive news about its Brilinta heart drug when the results of clinical trials are posted at the weekend lifted the shares 4.1pc to £44.79.

"Peers Shire and Glaxosmithkline were also big risers, putting on 2.7pc to £54.55 and 1.9pc to £15.48½ respectively. Glaxo was boosted by news it will sell half its stake in South Africa’s Aspen Pharmacare, which is expected to raise about $890m."

philanderer
12/3/2015
18:46
Sorry...got that earlier post on potential value of Aspen share sale totally wrong..... T/O is a little under £1 billion for the South African entity. Good news on AZN and hope there is more to come with GSK..Sorry again.
cyberian
12/3/2015
18:13
Might see a bid premium on GSK soon at this rate of future growth focus.
gwatson56
12/3/2015
18:09
"...Shares in Astrazeneca were lifted by comments from UBS which said that upcoming results from the Pegasus study of cardiovascular product Brilinta should drive "and thus should finally unlock Brilinta's multibillion-dollar potential". The bank said potential upside is "underappreciated" by the market.

"Sector peer GlaxoSmithKline also rose on plans to sell half of its 12.4% stake in South Africa's largest drug company, Aspen Pharmacare"

philanderer
12/3/2015
18:04
Deal? Or was it a Pharma correction as AZ also had a very good day?
jadeticl3
12/3/2015
17:59
Market liked that deal today :-)
philanderer
12/3/2015
13:41
Yeah - just read in full and not quite as impressive protection by vaccine as suggested by the abstract of the article. About 80% of vaccinated animals survived a challenge infection with Staph. aureus. Paper is in Proceedings National Academy of Sciences but you won't be able to access yet as only available pre-publication to registered users.
tompion
12/3/2015
09:39
Tompion do you have the article reference please? Not my field but sounds like an interesting read. Thanks!
yogaboy
12/3/2015
08:59
Interesting paper published today in top scientific journal by Novartis showing they have a new vaccine that gives very impressive protection against S. aureus/MRSA infection in an animal model. Early days but looks very promising (this is my field). If I remember correctly the vaccine portfolio of Novartis goes to GSK.
tompion
12/3/2015
08:56
12th march Deutsche 'hold'

reiterates

philanderer
12/3/2015
08:17
By better understanding our bodies' electrical systems, GSK hopes to design technology small and smart enough to manipulate them and possibly conquer diseases from rheumatoid arthritis to asthma to diabetes.

"If we look 10 years out, we should have a number of tiny devices—we call them bioelectronic medicines, because they are medicines—that will be treating conditions we use molecular medicines for today," Kris Famm, head of GSK's bioelectronics research and development unit, said in a telephone interview. "We are quite convinced this can be a class of new therapies."


The technology GSK envisions, which is also known as electroceuticals, would involve implanting tiny devices on nerve bundles associated with specific organ functions. Its broadest applications are still years from the market, but Famm said he thinks the biology is becoming well-enough understood that the challenge becomes one of engineering: being able to miniaturize electronic devices enough to very specifically stimulate certain nerves, and do so in an autonomous way, detecting and reacting to problems in the body. The approach should be so specific it avoids the off-target side effects that can derail otherwise promising medicines, he said.

tradermichael
11/3/2015
07:54
What would be the point of there being more than one broker if they said the same thing!
toffeeman
11/3/2015
07:33
Both have time machines set in opposite directions
tradermichael
10/3/2015
16:50
....couple more from the clever people ;-)

JP Morgan underweight tp 1250p
Barclays overweight tp 1690p

reiterations.

philanderer
10/3/2015
13:41
GlaxoSmithKline: Jefferies lifts target to 1550p from 1420p and reiterates hold
philanderer
09/3/2015
10:07
I stick to large cap shares in my approach. That means mostly FTSE100 and a very few from the FTSE250.
anhar
09/3/2015
08:18
Some interesting posts on High Yield Portfolios, and GSK certainly has a good fit into that strategy. The best Boards I've seen for HYP shares is over on MotleyFool under "Investors Roundtable" and called " High Yield - HYP Practical" and "High Yield - Share Strategies"



and

dragonsteeth
Chat Pages: Latest  423  422  421  420  419  418  417  416  415  414  413  412  Older

Your Recent History

Delayed Upgrade Clock